Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Cathelicidin Suppresses Colon Cancer Metastasis via a P2RX7-Dependent Mechanism.

Wang J, Cheng M, Law IKM, Ortiz C, Sun M, Koon HW.

Mol Ther Oncolytics. 2019 Jan 29;12:195-203. doi: 10.1016/j.omto.2019.01.004. eCollection 2019 Mar 29.

2.

Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.

Wang J, Ghali S, Xu C, Mussatto CC, Ortiz C, Lee EC, Tran DH, Jacobs JP, Lagishetty V, Faull KF, Moller T, Rossetti M, Chen X, Koon HW.

Gastroenterology. 2018 May;154(6):1737-1750. doi: 10.1053/j.gastro.2018.01.026. Epub 2018 Jan 31.

3.

CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway.

Xu C, Ghali S, Wang J, Shih DQ, Ortiz C, Mussatto CC, Lee EC, Tran DH, Jacobs JP, Lagishetty V, Fleshner P, Robbins L, Vu M, Hing TC, McGovern DPB, Koon HW.

Sci Rep. 2017 Nov 27;7(1):16351. doi: 10.1038/s41598-017-16753-z.

4.

Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.

Koon HW, Wang J, Mussatto CC, Ortiz C, Lee EC, Tran DH, Chen X, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01513-17. doi: 10.1128/AAC.01513-17. Print 2018 Jan.

5.

Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.

Tran DH, Wang J, Ha C, Ho W, Mattai SA, Oikonomopoulos A, Weiss G, Lacey P, Cheng M, Shieh C, Mussatto CC, Ho S, Hommes D, Koon HW.

BMC Gastroenterol. 2017 May 12;17(1):63. doi: 10.1186/s12876-017-0619-4.

6.

Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters.

Koon HW, Su B, Xu C, Mussatto CC, Tran DH, Lee EC, Ortiz C, Wang J, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C.

Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G610-G623. doi: 10.1152/ajpgi.00150.2016. Epub 2016 Aug 11.

7.

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor.

Hoang-Yen Tran D, Hoang-Ngoc Tran D, Mattai SA, Sallam T, Ortiz C, Lee EC, Robbins L, Ho S, Lee JE, Fisseha E, Shieh C, Sideri A, Shih DQ, Fleshner P, McGovern DP, Vu M, Hing TC, Bakirtzi K, Cheng M, Su B, Law I, Karagiannides I, Targan SR, Gallo RL, Li Z, Koon HW.

Int J Obes (Lond). 2016 Sep;40(9):1424-34. doi: 10.1038/ijo.2016.90. Epub 2016 May 10.

8.

Substance P mediates pro-inflammatory cytokine release form mesenteric adipocytes in Inflammatory Bowel Disease patients.

Sideri A, Bakirtzi K, Shih DQ, Koon HW, Fleshner P, Arsenescu R, Arsenescu V, Turner JR, Karagiannides I, Pothoulakis C.

Cell Mol Gastroenterol Hepatol. 2015 Jul 1;1(4):420-432.

9.

Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis.

Yoo JH, Ho S, Tran DH, Cheng M, Bakirtzi K, Kukota Y, Ichikawa R, Su B, Tran DH, Hing TC, Chang I, Shih DQ, Issacson RE, Gallo RL, Fiocchi C, Pothoulakis C, Koon HW.

Cell Mol Gastroenterol Hepatol. 2015 Jan;1(1):55-74.e1.

10.

Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts.

Cheng M, Ho S, Yoo JH, Tran DH, Bakirtzi K, Su B, Tran DH, Kubota Y, Ichikawa R, Koon HW.

Clin Exp Gastroenterol. 2014 Dec 17;8:13-29. doi: 10.2147/CEG.S70906. eCollection 2015.

11.

Endothelin-converting enzyme 1 and β-arrestins exert spatiotemporal control of substance P-induced inflammatory signals.

Jensen DD, Halls ML, Murphy JE, Canals M, Cattaruzza F, Poole DP, Lieu T, Koon HW, Pothoulakis C, Bunnett NW.

J Biol Chem. 2014 Jul 18;289(29):20283-94. doi: 10.1074/jbc.M114.578179. Epub 2014 Jun 4.

12.

Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.

Koon HW, Ho S, Hing TC, Cheng M, Chen X, Ichikawa Y, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2014 Aug;58(8):4642-50. doi: 10.1128/AAC.02783-14. Epub 2014 Jun 2.

13.

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, Pothoulakis C, Koon HW, Targan SR.

Mucosal Immunol. 2014 Nov;7(6):1492-503. doi: 10.1038/mi.2014.37. Epub 2014 May 21.

14.

Erratum: Sustained TL1A (TNFSF15) expression on both lymphoid and myeloid cells leads to mild spontaneous intestinal inflammation and fibrosis (DOI: 10.1556/EuJMI.3.2013.1.2).

Zheng L, Zhang X, Chen J, Ichikawa R, Wallace K, Pothoulakis C, Koon HW, Targan SR, Shih DQ.

Eur J Microbiol Immunol (Bp). 2013 Jun;3(2):141. doi: 10.1556/EuJMI.3.2013.2.8. Epub 2013 Jun 5. No abstract available.

15.

SUSTAINED TL1A (TNFSF15) EXPRESSION ON BOTH LYMPHOID AND MYELOID CELLS LEADS TO MILD SPONTANEOUS INTESTINAL INFLAMMATION AND FIBROSIS.

Zheng L, Zhang X, Chen J, Ichikawa R, Wallace K, Pothoulakis C, Koon HW, Targan SR, Shih DQ.

Eur J Microbiol Immunol (Bp). 2013 Mar;3(1):11-20. Erratum in: Eur J Microbiol Immunol (Bp). 2013 Jun;3(2):141.

16.

Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes.

Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X, Kelly CP, Targan SR, Pothoulakis C.

Antimicrob Agents Chemother. 2013 Jul;57(7):3214-23. doi: 10.1128/AAC.02633-12. Epub 2013 Apr 29.

17.

Differentiating functional roles of gene expression from immune and non-immune cells in mouse colitis by bone marrow transplantation.

Koon HW, Ho S, Cheng M, Ichikawa R, Pothoulakis C.

J Vis Exp. 2012 Oct 1;(68):e4208. doi: 10.3791/4208.

18.

Antimicrobial peptides and colitis.

Ho S, Pothoulakis C, Koon HW.

Curr Pharm Des. 2013;19(1):40-7. Review.

19.

The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice.

Hing TC, Ho S, Shih DQ, Ichikawa R, Cheng M, Chen J, Chen X, Law I, Najarian R, Kelly CP, Gallo RL, Targan SR, Pothoulakis C, Koon HW.

Gut. 2013 Sep;62(9):1295-305. doi: 10.1136/gutjnl-2012-302180. Epub 2012 Jul 3.

20.

Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis.

Barrett R, Zhang X, Koon HW, Vu M, Chang JY, Yeager N, Nguyen MA, Michelsen KS, Berel D, Pothoulakis C, Targan SR, Shih DQ.

Am J Pathol. 2012 Feb;180(2):636-49. doi: 10.1016/j.ajpath.2011.10.026. Epub 2011 Dec 2.

21.

Transgenic mice over-expressing ET-1 in the endothelial cells develop systemic hypertension with altered vascular reactivity.

Leung JW, Wong WT, Koon HW, Mo FM, Tam S, Huang Y, Vanhoutte PM, Chung SS, Chung SK.

PLoS One. 2011;6(11):e26994. doi: 10.1371/journal.pone.0026994. Epub 2011 Nov 11.

22.

Substance P induces CCN1 expression via histone deacetylase activity in human colonic epithelial cells.

Koon HW, Shih DQ, Hing TC, Chen J, Ho S, Zhao D, Targan SR, Pothoulakis C.

Am J Pathol. 2011 Nov;179(5):2315-26. doi: 10.1016/j.ajpath.2011.07.038. Epub 2011 Sep 23.

23.

Cathelicidin signaling via the Toll-like receptor protects against colitis in mice.

Koon HW, Shih DQ, Chen J, Bakirtzi K, Hing TC, Law I, Ho S, Ichikawa R, Zhao D, Xu H, Gallo R, Dempsey P, Cheng G, Targan SR, Pothoulakis C.

Gastroenterology. 2011 Nov;141(5):1852-63.e1-3. doi: 10.1053/j.gastro.2011.06.079. Epub 2011 Jul 14.

24.

Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis.

Shih DQ, Barrett R, Zhang X, Yeager N, Koon HW, Phaosawasdi P, Song Y, Ko B, Wong MH, Michelsen KS, Martins G, Pothoulakis C, Targan SR.

PLoS One. 2011 Jan 11;6(1):e16090. doi: 10.1371/journal.pone.0016090.

25.

Insulin-like growth factor-1 receptor transactivation modulates the inflammatory and proliferative responses of neurotensin in human colonic epithelial cells.

Zhao D, Bakirtzi K, Zhan Y, Zeng H, Koon HW, Pothoulakis C.

J Biol Chem. 2011 Feb 25;286(8):6092-9. doi: 10.1074/jbc.M110.192534. Epub 2011 Jan 6.

26.

Substance P modulates colitis-associated fibrosis.

Koon HW, Shih D, Karagiannides I, Zhao D, Fazelbhoy Z, Hing T, Xu H, Lu B, Gerard N, Pothoulakis C.

Am J Pathol. 2010 Nov;177(5):2300-9. doi: 10.2353/ajpath.2010.100314. Epub 2010 Oct 1.

27.

Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice.

Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Zhao D, Kokkotou EG, Pothoulakis C, Kelly CP.

Gastroenterology. 2009 Sep;137(3):914-23. doi: 10.1053/j.gastro.2009.05.050. Epub 2009 May 29.

28.

Neurotensin induces IL-6 secretion in mouse preadipocytes and adipose tissues during 2,4,6,-trinitrobenzensulphonic acid-induced colitis.

Koon HW, Kim YS, Xu H, Kumar A, Zhao D, Karagiannides I, Dobner PR, Pothoulakis C.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8766-71. doi: 10.1073/pnas.0903499106. Epub 2009 May 14.

29.

Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways.

Gross K, Karagiannides I, Thomou T, Koon HW, Bowe C, Kim H, Giorgadze N, Tchkonia T, Pirtskhalava T, Kirkland JL, Pothoulakis C.

Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1012-9. doi: 10.1152/ajpgi.90351.2008. Epub 2009 Mar 12.

30.

Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis.

Koon HW, Zhao D, Xu H, Bowe C, Moss A, Moyer MP, Pothoulakis C.

Am J Pathol. 2008 Aug;173(2):400-10. doi: 10.2353/ajpath.2008.080222. Epub 2008 Jul 3.

31.

Substance P mediates antiapoptotic responses in human colonocytes by Akt activation.

Koon HW, Zhao D, Zhan Y, Moyer MP, Pothoulakis C.

Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):2013-8. Epub 2007 Jan 30.

32.
33.

Immunomodulatory properties of substance P: the gastrointestinal system as a model.

Koon HW, Pothoulakis C.

Ann N Y Acad Sci. 2006 Nov;1088:23-40. Review.

PMID:
17192554
34.

Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic epithelial cells.

Koon HW, Zhao D, Zhan Y, Rhee SH, Moyer MP, Pothoulakis C.

J Immunol. 2006 Apr 15;176(8):5050-9.

35.

Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves protein kinase Cdelta activation.

Koon HW, Zhao D, Zhan Y, Simeonidis S, Moyer MP, Pothoulakis C.

J Pharmacol Exp Ther. 2005 Sep;314(3):1393-400. Epub 2005 May 25.

PMID:
15917399
36.

Clostridium difficile toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes.

Na X, Zhao D, Koon HW, Kim H, Husmark J, Moyer MP, Pothoulakis C, LaMont JT.

Gastroenterology. 2005 Apr;128(4):1002-11.

PMID:
15825081
37.

Neurotensin stimulates interleukin-8 expression through modulation of I kappa B alpha phosphorylation and p65 transcriptional activity: involvement of protein kinase C alpha.

Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C.

Mol Pharmacol. 2005 Jun;67(6):2025-31. Epub 2005 Mar 8.

PMID:
15755906
38.
39.

Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells.

Zhao D, Zhan Y, Koon HW, Zeng H, Keates S, Moyer MP, Pothoulakis C.

J Biol Chem. 2004 Oct 15;279(42):43547-54. Epub 2004 Jul 6.

40.

Supplemental Content

Support Center